Background Most symptoms of coronavirus 2019 (COVID-19) are mild; however, some
patients experience cardiovascular complications, including thromboembolic events and …

Introduction The incidence of thromboembolism during COVID-19 and the use of
thromboprophylaxis vary greatly between studies. Only a few studies have investigated the …

PURPOSE: The novel coronavirus SARS-CoV-2, better known as COVID-19, has been
shown to have major thromboembolic complications. Data supports pharmacologic …

Background Cardiovascular complications, including myocardial infarction, ischemic stroke,
and pulmonary embolism, represent an important source of adverse outcomes in …

Introduction One of the most prominent and concerning complications associated with
coronavirus disease 2019 (COVID-19) is venous and arterial thromboembolisms. The aim of …

Background Thrombotic events can increase the COVID-19 associated disease mortality.
The administration of prophylactic anticoagulants had been shown to decrease the …

Abstract Background Coronavirus disease 2019 (COVID‐19) is associated with high rates of
thromboembolic events in hospitalized patients. It remains to be determined if this risk …

Introduction Thromboembolic outcomes have emerged as an important issue in sick
hospitalized patients with COVID-19. Multiple pathogenetic mechanisms for thrombosis …

Objectives: The potential benefit of routine prophylactic anticoagulation for all hospitalized
patients with clinically stable coronavirus disease 2019 (COVID-19) is still controversial …

Background Coronavirus disease 2019 (COVID-19) increases thrombosis in hospitalized
patients prompting adoption of different thromboprophylaxis strategies. Safety and efficacy of …